Navigation Links
Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show
Date:11/10/2016

Speaking at the Sensors and Graphene & 2D Materials events on November 16 and 17, the two co-founders of Nanomedical Diagnostics will present the proprietary Field Effect Biosensing (FEB) technology behind AGILE R100, a breakthrough label-free biosensor assay.

Small emerging therapeutics companies evaluate binding affinities to confirm hits and optimize leads. “Surface plasmon resonance (SPR) and Bio-Layer Interferometry (BLI) platforms for kinetic analysis cost well over $150,000, which is out of range for most small biotechs,” explains CEO Ross Bundy. “As a result, biophysical testing is outsourced, which adds time and cost to evaluating hits. With the FEB technology behind AGILE R100, researchers can gain sensitive real-time kinetic binding data at their bench in less than a day. This enables scientists to take control of their lead optimization, no matter the size of their lab.”

AGILE R100 is a benchtop label-free assay built with proprietary FEB technology that enables miniaturization and cost-efficiency. The non-optical technique measures current across a field effect biosensor surface immobilized with capture molecules. Binding that occurs on the surface changes the current that is monitored in real-time, enabling accurate affinity, kinetics, and concentration data.

CTO Dr. Brett Goldsmith underscores additional capabilities FEB brings to drug discovery over traditional SPR and BLI methods. “SPR and BLI struggle with small molecules, high concentrations of analyte, measurement in DMSO, and small sample sizes. Because FEB is a charge-based technique, not an optical one, it has no difficulty measuring small molecules down to 1 Dalton as well as larger molecules. High concentrations and DMSO cause no problems for AGILE R100 because there are no optical limitations. And FEB is a highly-sensitive technology, which enables use of just 10 microliters of sample.”

In addition to IDTechEx, Nanomedical Diagnostics will present AGILE R100 at the American Society for Cell Biology Conference in San Francisco from December 4 through December 6.

AGILE R100 is available for commercial sale, for research use only. For more information, visit http://www.nanomedicaldiagnostics.com.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough all-electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and concentration data. AGILE biosensor chips at the heart of the assay leverage the highly sensitive nanomaterial graphene to unite biology with electronics, delivering the unique ability to sense small molecules with no lower size limit in complex media such as DMSO, and use unprecedentedly small amounts of sample.

Read the full story at http://www.prweb.com/releases/Nanomedical_Diagnostics/AGILE_R100_at_IDTechEx/prweb13839905.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Nanomedical Diagnostics launches a new graphene biosensor with unprecedented functionality for small molecule and protein analysis
2. Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers
3. BioGenex Boosts Genome Research and Diagnostics with the Launch of the Xmatrx Mini for Simplified FISH, ISH, and In Situ PCR Analysis of Histology and Cytology Specimens
4. Valery Tuchin Honored with Joseph W. Goodman Award for Book on Light Scattering Applications in Medical Diagnostics
5. Provista Diagnostics Study First to Show that Age Should Be Considered When Developing Diagnostic Assays
6. Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination
7. Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
8. Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health
9. Provista Diagnostics Appoints Susan Gross, M.D., as Chief Medical Officer
10. Quest Diagnostics Completes Acquisition of Clinical Laboratory Partners Outreach Laboratory Service Business in Connecticut
11. Europe Molecular Diagnostics Market to Reach US$4.2 bn by 2023, Adoption of Next Generation Sequencing Technologies Rapidly Rise: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2017)... Haven, CT (PRWEB) , ... June 15, 2017 ... ... today that it has secured a Series B round of financing in the ... and a group of private investors participated in the round. , The Series ...
(Date:6/15/2017)... ... 2017 , ... DuPont Industrial Biosciences (DuPont) announced that Jan ... Bloomberg’s 2017 Sustainable Business Summit: Seattle this Thursday, June 15, at 4:10 ... panel titled “Developing a Corporate Renewables Strategy.” , “Consumers want to buy ...
(Date:6/14/2017)... ... 14, 2017 , ... The Thailand Board of Investment (BOI) ... co-hosting a delegation from Thailand at BIO 2017 in San Diego, CA taking ... the world, regroups more than 1,100 biotech companies, academic institutions, state biotechnology centers ...
(Date:6/14/2017)... Village, CA (PRWEB) , ... June 14, 2017 ... ... LiquidBiopsy® cancer diagnostics and personalized medicine technology, today announced four new distribution agreements ... monitoring over the cancer care cycle. The commercial agreements will make ClearID available ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):